- Home
- GERN vs SABR Comparison
GERN vs SABR Comparison
Compare GERN & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- SABR
- Stock Information
- Founded
- GERN 1990
- SABR 2006
- Country
- GERN United States
- SABR United States
- Employees
- GERN N/A
- SABR N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- SABR Computer Software: Programming Data Processing
- Sector
- GERN Health Care
- SABR Technology
- Exchange
- GERN Nasdaq
- SABR Nasdaq
- Market Cap
- GERN 740.5M
- SABR 836.4M
- IPO Year
- GERN 1996
- SABR 2014
- Fundamental
- Price
- GERN $1.12
- SABR $1.72
- Analyst Decision
- GERN Buy
- SABR Buy
- Analyst Count
- GERN 7
- SABR 5
- Target Price
- GERN $3.00
- SABR $4.12
- AVG Volume (30 Days)
- GERN 8.6M
- SABR 7.8M
- Earning Date
- GERN 11-05-2025
- SABR 11-05-2025
- Dividend Yield
- GERN N/A
- SABR N/A
- EPS Growth
- GERN N/A
- SABR N/A
- EPS
- GERN N/A
- SABR 1.41
- Revenue
- GERN $183,403,000.00
- SABR $3,034,040,000.00
- Revenue This Year
- GERN $166.20
- SABR N/A
- Revenue Next Year
- GERN $55.83
- SABR $3.91
- P/E Ratio
- GERN N/A
- SABR $1.21
- Revenue Growth
- GERN 522.13
- SABR 8.86
- 52 Week Low
- GERN $1.04
- SABR $1.69
- 52 Week High
- GERN $4.21
- SABR $4.63
- Technical
- Relative Strength Index (RSI)
- GERN 40.96
- SABR 35.73
- Support Level
- GERN $1.04
- SABR $1.78
- Resistance Level
- GERN $1.28
- SABR $2.00
- Average True Range (ATR)
- GERN 0.07
- SABR 0.12
- MACD
- GERN 0.00
- SABR -0.03
- Stochastic Oscillator
- GERN 30.12
- SABR 5.21
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company sold its growing hotel IT solutions division (9% of revenue) to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.